藥品參考
Retifanlimab
Retifanlimab is a medicine in the class oncology. It is used for anal carcinoma.
- 藥物類別: Oncology
- 用途: anal carcinoma
最後更新 來源: EMA SmPC
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
重點資訊
- 藥物類別
- Oncology
- ATC 代碼
- L01FF10
- 常見劑型
- 注射劑
- 常見規格
- 25 mg/ml
- 已知交互作用
- 4 (中度: 3 · 輕微: 1)
- 商品名
- 2
- 國家與市場
- 2
用途
作用方式
Retifanlimab is an IgG4 monoclonal antibody that binds PD-1 and blocks its interaction with PD-L1 and PD-L2, potentiating T-cell activity.
成人常用劑量（仿單摘要）
Squamous cell carcinoma of the anal canal: 500 mg IV infusion over 30 minutes every 4 weeks with carboplatin and paclitaxel for 6 cycles, then 500 mg monotherapy every 4 weeks; continue until progression or unacceptable toxicity, up to 1 year
懷孕與哺乳
- 懷孕
- Unsafe Can cause fetal harm: PD-1 blockade can break immune tolerance to the fetus and lead to fetal loss; IgG4 crosses the placenta. No human or animal reproduction data. Not recommended in pregnancy; check pregnancy status and use contraception for 4 months after the last dose.
- 哺乳
- Unsafe No milk data; likely low and poorly absorbed. US label: do not breastfeed during treatment and for 4 months after the last dose. EU label: risk only in the first days after birth; afterwards it may be used if needed. LactMed: manufacturer advice to avoid.
已通報的副作用
- Fatigue
- Rash
- Diarrhoea
- Anaemia
- Pruritus
- Arthralgia
禁忌症
- Hypersensitivity to the active substance or to any excipient.
哪些人需要特別留意
- Immune-related adverse reactions, which may be severe or fatal, can affect any organ; monitor and manage with withholding or discontinuation and corticosteroids.
- Infusion-related reactions can be severe; monitor and interrupt, slow or discontinue based on severity.
- Combination with carboplatin and paclitaxel increased the risk and severity of neutropaenia; frequent haematological monitoring is recommended.
請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。
重要交互作用 (4)
- Piperacillin + Retifanlimab Moderate
- Piperacillin-tazobactam + Retifanlimab Moderate
- Prednisone + Retifanlimab Moderate
- Penicillin g + Retifanlimab Minor
Pro+ 會員專屬
解鎖完整頁面
建立帳號並開始 Pro+ 試用，即可開啟 Retifanlimab 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Dosing in older adults
- How to give it
- Pharmacokinetics
- Patient counselling points
- IV preparation and dilution
在網頁版免費試用 Pro+ 14 天，無需信用卡。
同類別的其他藥品
常見問題
What is Retifanlimab used for?
Retifanlimab is a medicine in the class oncology. It is used for Anal carcinoma.
What side effects have been reported with Retifanlimab?
Fatigue, Rash, Diarrhoea, Anaemia, Pruritus, Arthralgia.
Can Retifanlimab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: PD-1 blockade can break immune tolerance to the fetus and lead to fetal loss; IgG4 crosses the placenta. No human or animal reproduction data. Not recommended in pregnancy; check pregnancy status and use contraception for 4 months after the last dose. Breastfeeding: Unsafe. No milk data; likely low and poorly absorbed. US label: do not breastfeed during treatment and for 4 months after the last dose. EU label: risk only in the first days after birth; afterwards it may be used if needed. LactMed: manufacturer advice to avoid.
What does Retifanlimab interact with?
MediHelp lists 4 known interactions for Retifanlimab. Moderate: 3 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Prednisone.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
